Covid 19 coronavirus: Vaccine candidate approved for military use in China

CanSino's COVID-19 vaccine candidate approved for military use in China

Chinese military have been cleared to receive a Covid-19 vaccine.

Organisations around the world are racing to find ways to treat and prevent the deadly pathogen, which first emerged in the central Chinese city of Wuhan and has since killed over half a million people worldwide.

The British drug maker is already carrying out large-scale, mid-stage human trials of the vaccine, which was developed by researchers at Oxford University.

"At the moment, we do not have a proven vaccine but if we are lucky, there will be one or two successful candidates before the end of this year", Swaminathan said while addressing the media from Geneva.

The vaccine was jointly produced by Chinese biopharmaceutical firm CanSino Biologics Inc and Institute of Biotechnology under the Academy of Military Medical Sciences. To stop it replicating, the virus is made inactive by removing certain genes. Once injected, these viral antigens are expressed in human cells that trigger the body's immune response.

The Ad5-nCoV vaccine candidate appeared in reports in mid-May when CanSino published the results of Phase 1 testing.

Brazil announced on Saturday that it had signed a $127 million agreement to start producing locally an experimental vaccine developed by AstraZeneca that has shown promise to fight the Covid-19 pandemic.

"They have advanced into Phase 2 trials and are planning Phase 3 in many countries".

The Phase 1 and Phase 2 clinical trials showed the vaccine candidate has potential to prevent diseases caused by the coronavirus, which has killed half a million people globally, but its commercial success can not be guaranteed, the company said.

Another 131 candidate vaccines listed by the World Health Organization are in the pre-clinical phase.

No vaccine has yet been approved for commercial use against the illness caused by the new coronavirus.



Other news